OverviewChartProfileKey statisticsFinancialsTechnicalNews
Derivatives
TraderScreen

Regeneron Pharmaceuticals Inc/  US75886F1075  /

NASDAQ
2024-11-08  10:00:00 PM Chg. +3.9400 Volume Bid12:04:31 AM Ask12:04:31 AM Market Capitalization Dividend Y. P/E Ratio
828.4200USD +0.48% 563,585
Turnover: 272.09 mill.		 828.5000Bid Size: 100 855.0000Ask Size: 100 91.03 bill.USD - 22.36

Business description

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
 

Management board & Supervisory board

CEO
Dr. Leonard S. Schleifer
Management board
Robert E. Landry, Dr. George D. Yancopoulos
Supervisory board
Arthur F. Ryan, Christine A. Poon, Craig B. Thompson, Dr. Bonnie L. Bassler, Dr. George D. Yancopoulos, Dr. Leonard S. Schleifer, Dr. Marc Tessier-Lavigne, George L. Sing, Huda Y. Zoghbi, M.D., Joseph L. Goldstein, M.D., Michael S. Brown, M.D., Tony Coles, M.D.
 

Company data

Name: Regeneron Pharmaceuticals Inc.
Address: 777 Old Saw Mill River Road,Tarrytown, New York 10591-6707, USA
Phone: +1-914-847-7000
Fax: -
E-mail: -
Internet: is.gd/sEAmh8
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12-31
Free Float: 68.40%
IPO date: 1991-04-12

Investor relations

Name: -
IR phone: +1-914-847-7741
IR Fax: -
IR e-mail: invest@regeneron.com

Main Shareholders

Others
 
 50.26%
FMR LLC.
 
 9.52%
Vanguard Group
 
 8.16%
BlackRock Inc.
 
 7.96%
JP Morgan Chase & Co.
 
 6.67%
Capital World Investors
 
 4.73%
State Street Corporation
 
 4.52%
Capital International Investors
 
 2.69%
Dodge & Cox
 
 2.18%
Others
 
 3.30%